[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholecystectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholecystectomy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,53,99,134,158,183,210,243,267,289,311],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100641844","eus-guided-gallbladder-drainage-versus-conservative-management-in-patients-unfit-for-surgery-after-a-biliary-event-without-cholecystitis-drecon-study-100641844",false,"NCT07655778","EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study","Multicenter Comparative Clinical Trial: EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study: (DRainage, Endoscopic Ultrasound, CONservative)","DRECON","Inclusion Criteria:\n\n* Patients ≥ 18 years of age\n* Patients who have experienced a benign biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis) and are candidates for elective cholecystectomy\n* Patients deemed unfuit for surgery (age ≥ 80 years, ASA score ≥ 3, Charlson Comorbidity Index ≥ 5) or who voluntarily refuse surgery\n* Diagnosis of lithogenic\u002Flithiasic material in the gallbladder by imaging (biliary sludge, microlithiasis, and\u002For cholelithiasis)\n* Signed informed consent\n\nExclusion Criteria:\n\n* No signed informed consent\n* Prior cholecystectomy\n* Biliary event secondary to malignant etiology\n* Acute cholecystitis diagnosed according to Tokyo 2018 criteria\n* Moderate-to-severe ascites without prior paracentesis\n* Perforated gallbladder\n* Severe coagulopathy (INR \\> 1.5) or thrombocytopenia (platelets \\\u003C 50,000\u002FμL) not correctable\n* Any clinical condition preventing sedation\n* Patient dependent for daily activities (ECOG ≥ 4)","ALL","18 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cholecystectomy is considered the standard definitive treatment after an acute biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis). However, in elderly patients and\u002For those with significant comorbidities, surgery is often not feasible, leaving this population at high risk of biliary event recurrence (approximately 25-31% per year without treatment).\n\nEUS-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS) is an established endoscopic technique currently recommended for acute cholecystitis in patients unfit for surgery. It creates an internal fistula between the gallbladder and the adjacent digestive tract, allowing direct endoscopic access for stone clearance (cholecystoscopy). This approach could theoretically prevent biliary event recurrence similarly to cholecystectomy.\n\nThe DRECON study (DRainaige, Endoscopic ultrasound, CONservative) is a multicenter, randomized, comparative clinical trial evaluating whether EUS-GBD with LAMS reduces biliary recurrence at 1 year compared to conservative managment (CM) in patients unfit for surgery after a biliary event without acute cholecystitis who are candidates for elective cholecystectomy.\n\nPrimary hypothesis: EUS-GBD will reduce the risk of biliary event recurrence (biliary colic, acute pancreatitis, cholangitis, choledocholithiasis, or cholecystitis) at 1 year of follow-up compared to conservative management in patients unfit for surgery with gallbladder lithiasis.\n\nEstimated sample: 110 patients (55 per arm). Randomization 1:1 (EUS-GBD vs CM), stratified by centre and prior biliary sphincterotomy. Duration: 24 months recruitment + 12 months follow-up (total 3 years).\n\nParticipating centres: Hospital Universitari Mútua de Terrassa (coordinating centre), Hospital Universitari de Bellvitge, Hospital General de Granollers, Hospital Universitari Parc Taulí de Sabadell, Hospital Universitari de la Santa Creu i Sant Pau, Hospital Clínico Universitario de Valencia, Hospital General Universitario Dr Balmis and Complexo Hospitalario Universitario de A Coruña.",[27,28,29,30,31,32,33,34],"Cholecystectomy","Gallbladder","Endoscopic Ultrasound (EUS)","Cholelithiasis","Acute Pancreatitis Due to Common Bile Duct Calculus","Biliary Colic","Acute Pancreatitis Due to Gallstones","Cholangitis; Choledocholithiasis",[36,37,38,39,40,29],"gallbladder","gallblader drainage","conservative treatment","biliary recurrence","cholecystectomy","NOT_YET_RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-22","ACTUAL",{"date":47,"type":21},"2026-07-01",{"date":49,"type":21},"2029-07-01",{"name":51,"class":52},"Hospital Mutua de Terrassa","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":85,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100567703","stanford-program-to-accelerate-robotic-childrens-surgery-100567703","NCT06671639","Stanford Program to Accelerate Robotic Children's Surgery","SPARCS","Inclusion Criteria:\n\n1. Subject is between 6 - 21 years of age (weighing at least 15 kilograms)\n2. Subject clinically diagnosed with a medical condition for which one of the study procedures is appropriate therapy and selected as the treatment of choice by the guardian and surgeon.\n3. Subject without previous treatment using a robotic surgery device\n4. Subject or their guardian is willing and able to provide written informed consent\n5. Subject or their guardian is willing and able to comply with the study protocol requirements\n\nExclusion Criteria:\n\n1. Subject with uncorrected coagulopathy\n2. Subject has clinical requirement for primary open operative procedure\n3. Subject is ASA 4 or 5 status\n4. Subject is contraindicated for general anesthesia or surgery\n5. Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent\n6. Subject is pregnant or suspected to be pregnant","6 Years","21 Years",{"count":63,"type":21},250,[24],"The goal of this clinical trial is to provide additional data to confirm safety and performance of the da Vinci Xi Surgical System in a human clinical setting. This pilot study is intended to provide an initial assessment to evaluate the feasibility, safety, and effectiveness for the utilization of the da Vinci Xi on pediatric and adolescent patients. This clinical trial will be conducted under the auspices of Stanford University's IRB approval.",[67,27,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84],"Sleeve Gastrectomy","Splenectomy","Hysterectomy","Endometriosis","Ureteral Re-implant","Cervical and Thoracic Tracheoplasty","Thymectomy","Lobectomy\u002FWedge Lung Resection","Lung Segmentectomy","Bronchoplasty","Endoscopic Laryngeal\u002FPharyngeal Suturing","Vocal Feminization","Laryngeal Cleft Repair","Endolaryngeal Adjacent Tissue Transfer","Pharyngoplasty","Ileocolonic Resections","Laryngoplasty","Proctectomy With Ileal Pouch-Anal Anastomosis",[86,87],"Robotic Surgery","Pediatric Robotic Surgery","RECRUITING","2026-04-24",{"date":91,"type":45},"2026-04-30",{"date":93,"type":45},"2025-08-01",{"date":95,"type":21},"2028-02-28",{"name":97,"class":52},"Stanford University",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":112,"conditions":113,"keywords":120,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":98},"100592679","phase-2-exploring-the-impact-of-genetic-variations-on-the-clinical-efficacy-of-nalbuphine-in-postoperative-pain-management-100592679","NCT06996561","Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management","Nal","Inclusion Criteria:\n\n1. All adult men or women\n2. Age 18 to 70 years\n3. ASA criteria 1,2 and 3\n4. Abdomino-pelvic surgeries (open hernia repair, appendicectomy, open cholecystectomy, laparotomy, hysterectomy, cystectomy) lasting 2-4 hours\n\nExclusion Criteria:\n\n1. Surgical procedure duration lasting more than 4 hours\n2. Patients taking anti fungal fluconazole, anticoagulant (Warfarin or Clopidogrel) SNRI (Amitryptalline), Rifampicin or Buprenorphine,\n3. History of hypersensitivity or allergy to opioids,\n4. Pregnant or breastfeeding mothers,\n5. History of narcotic dependency, addiction, and withdrawal\n6. Patients experiencing any adverse side effects or complications during surgical procedure requiring intensive care admission\n7. Refusing to participate in the study\n8. Surgical procedures utilizing other modes of intraoperative analgesia e.g epidural analgesia or nerve blocks","70 Years",{"count":108,"type":21},263,[110,111],"PHASE2","PHASE3","The goal of this study is to identify the genes as well as their association with Nalbuphine. This will help the investigator to identify opioid vulnerability in Pakistani population in the postoperative patients and will contribute to overcoming the opioid crisis, resulting in better and safer outcomes.\n\nResearch question is:\n\nIs there any association between the underlying genetic variations and the analgesic efficacy of Nalbuphine in postoperative patients? The Research Objectives are\n\n1. To identify the underlying genes in postoperative patients having pain.\n2. To find an association between identified genes and nalbuphine clinical efficacy.\n\nProcedure: After the written informed consent adult men and women will be enrolled in the study. On the day of surgery in the preoperative area, a 5 ml blood sample will be drawn before surgery and will be sent to laboratory for analysis. After routine hemodynamic monitoring in the operative room, general anesthesia will be given including nalbuphine. Standard routine anesthesia monitoring will be done and maintained while monitoring heart rate, ECG, NIBP oxygen saturation, ETCO2 and temperature. Incremental analgesia will be provided whenever needed. After extubation and shifting to recovery room the 2nd sample of blood will be taken and will be sent for analysis. Pain score, nausea vomiting, sedation, requirement of analgesia will be assessed till 24 hours postoperatively.",[27,114,115,116,117,118,69,119],"Hernia, Abdominal","Appendectomy","Open Colorectal Surgery","Laparatomy","Postoperative Pain","Cystectomy",[121,122,123,124],"genetic variations","nalbuphine","opioids","polymorphism","2026-04-14",{"date":127,"type":45},"2026-04-15",{"date":129,"type":45},"2025-09-01",{"date":131,"type":21},"2027-06-30",{"name":133,"class":52},"Dr. Asma Abdus Salam",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100633945","erector-spinae-plane-block-versus-external-oblique-intercostal-plane-block-for-analgesia-in-open-cholecystectomy-100633945","NCT07533279","Erector Spinae Plane Block Versus External Oblique Intercostal Plane Block for Analgesia in Open Cholecystectomy","Efficacy of Bilateral Erector Spinae Plane Block Versus Bilateral External Oblique Intercostal Plane Block for Perioperative Analgesia in Open Cholecystectomy Surgeries: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged 18-65 years.\n* Patients scheduled for elective open cholecystectomy.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n* Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Known allergy to local anesthetics.\n* Coagulopathy or anticoagulant therapy.\n* Infection at the site of injection.\n* Severe hepatic, renal, or cardiac disease.\n* Body mass index (BMI) \\> 35 kg\u002Fm².\n* Pregnancy.","65 Years",{"count":143,"type":21},66,[24],"This randomized controlled trial aims to compare the analgesic efficacy of bilateral ultrasound-guided erector spinae plane block (ESPB) versus bilateral external oblique intercostal plane (EOI) block in patients undergoing open cholecystectomy.\n\nPatients will be randomly allocated into two groups to receive either ESPB or EOI block in addition to standard general anesthesia. The primary outcome is postoperative pain score assessed using the Numerical Rating Scale (NRS) at 2 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative nalbuphine requirements, time to first analgesic request, and hemodynamic changes.\n\nThis study seeks to determine the more effective regional anesthesia technique for improving perioperative analgesia in open cholecystectomy.",[27,118,147,148],"Erector Spinae Plane Block","Regional Anesthesia","2026-04-09",{"date":151,"type":45},"2026-04-16",{"date":153,"type":21},"2026-06",{"date":155,"type":21},"2027-05",{"name":157,"class":52},"Sohag University",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":165,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":166,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":98},"100626746","peg-laxatives-for-intestinal-preparation-and-gut-microbiota-in-cholecystectomy-100626746","NCT07439640","PEG Laxatives for Intestinal Preparation and Gut Microbiota in Cholecystectomy","Clinical Experimental Study on the Impact of PEG Laxatives for Intestinal Preparation on Gut Microbiota in Patients Undergoing Cholecystectomy","Inclusion Criteria:\n\n* Scheduled to undergo colonoscopy with polyethylene glycol (PEG)-based bowel preparation.\n* For the gallbladder removal group: prior cholecystectomy performed at least 6 months before enrolment.\n* For the normal group: intact gallbladder (no history of cholecystectomy).\n* Willing and able to provide written informed consent.\n* Willing to collect and mail stool samples at five specified time points (baseline, first non-watery stool after colonoscopy, 1 month, 3 months, 6 months).\n\nExclusion Criteria:\n\n* Contraindications to colonoscopy (e.g., severe cardiopulmonary insufficiency, acute gastrointestinal bleeding, severe coagulopathy).\n* Known intolerance or allergy to polyethylene glycol (PEG).\n* Use of antibiotics, probiotics, or prebiotics within 6 months prior to enrolment.\n* Pregnancy or breastfeeding.\n* Mental disorders or any condition that may compromise the ability to comply with study procedures.\n* Major organ diseases (e.g., liver cirrhosis, chronic kidney disease stage 4-5, uncontrolled diabetes mellitus).\n* Participation in another interventional clinical trial within the last 3 months.",true,{"count":167,"type":21},20,"OBSERVATIONAL","This observational study aims to investigate the impact of polyethylene glycol (PEG) laxatives used for bowel preparation on the gut microbiota of patients who have undergone cholecystectomy. Emerging evidence suggests that both cholecystectomy and high-dose PEG exposure can independently alter the intestinal microbial ecosystem. However, whether the microbiota of post-cholecystectomy patients is more vulnerable to PEG-induced perturbation and exhibits delayed recovery remains unknown.\n\nApproximately 10 adults with prior cholecystectomy scheduled for colonoscopy and 10 age-matched controls without cholecystectomy will be enrolled. All participants will undergo standard colonoscopy preparation with PEG-based laxatives. Stool samples will be collected at five time points: before bowel preparation, at the first non-watery stool after colonoscopy, and at 1, 3, and 6 months post-colonoscopy. Metagenomic shotgun sequencing will be performed to characterise the taxonomic and functional profiles of the gut microbiome. Alpha diversity, beta diversity, differential abundance, and metabolic pathway alterations will be compared within and between groups over time.\n\nThe findings are expected to reveal whether cholecystectomised individuals are more susceptible to long-term gut dysbiosis after PEG exposure, and to inform future strategies for microbiota restoration in this specific population.",[27],[172,173],"Gut Microbiota","Colonoscopy","2026-02-23",{"date":176,"type":45},"2026-02-27",{"date":178,"type":45},"2025-01-16",{"date":180,"type":21},"2027-03-16",{"name":182,"class":52},"Tongji Hospital",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":98},"100623715","laparoscopic-ultrasound-versus-fluorescence-cholangiography-in-technically-challenging-laparoscopic-cholecystectomy-100623715","NCT07400237","Laparoscopic Ultrasound Versus Fluorescence Cholangiography in Technically Challenging Laparoscopic Cholecystectomy","Laparoscopic Ultrasound Versus Fluorescence Cholangiography in Technically Challenging Laparoscopic Cholecystectomy. Multicenter Comparative Study","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Written informed consent provided.\n3. Indication for laparoscopic cholecystectomy with anticipated technical difficulty due to one or more of the following:\n\n   * Acute cholecystitis.\n   * Previous cholangitis, pancreatitis, or endoscopic retrograde cholangiopancreatography.\n   * Prior upper abdominal surgery.\n   * Obesity (Body Mass Index ≥ 30 kg\u002Fm²).\n\nExclusion Criteria:\n\n1. Known allergy to ICG or iodine.\n2. Pregnancy or breastfeeding.\n3. High risk of choledocholithiasis (ESGE guidelines).\n4. Thyroid disease.\n5. Suspected gallbladder malignancy.\n6. ASA class IV-V.\n7. Chronic kidney disease stage \\> IIIb.\n8. Planned open cholecystectomy.",{"count":191,"type":21},62,[24],"This is a multicenter, prospective, interventional clinical trial designed to evaluate and compare two intraoperative imaging modalities: laparoscopic ultrasound (LUS) and fluorescence cholangiography with indocyanine green (ICG), for the identification of biliary anatomy in technically challenging laparoscopic cholecystectomy. All enrolled subjects will undergo both LUS and ICG during the index procedure, following a standardized sequence, in order to allow intra-subject comparison. LUS will be performed first, followed by fluorescence cholangiography prior to Calot's triangle dissection.\n\nThe primary endpoint is the successful identification of the critical junction. Secondary endpoints include visualization of individual biliary structures, time to visualization, total operative time, intraoperative and postoperative complications.",[27],[196,197,198,199,200],"laparoscopic cholecystectomy","laparoscopic ultrasound","fluorescence cholangiography","indocyanine green","biliary injury prevention","2026-02-03",{"date":203,"type":45},"2026-02-10",{"date":205,"type":45},"2025-04-01",{"date":207,"type":21},"2027-12",{"name":209,"class":52},"Consorci Sanitari Integral",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":227,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":98},"100602107","surgical-techniques-robotic-versus-conventional-laparoscopic-cholecystectomy-in-benign-gallbladder-disease-100602107","NCT07119203","Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease","Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease: A Randomized Controlled, Open, Parallel, Non-inferiority, Single-center Trial (STaRLING Trial)","STaRLING","Inclusion Criteria:\n\n* Age equal or above 18 years;\n* Benign gallbladder disease: diagnosis of gallbladder polyps or symptomatic gallstones proven on imaging (ultrasound, computed tomography (CT) scan or magnetic resonance cholangiopancreatography (MRCP));\n* Capacity to give informed consent.\n\nExclusion Criteria:\n\n* Minimally invasive procedure is not deemed possible by the operating surgeon;\n* Evidence of acute cholecystitis;\n* Known stones in the common bile duct (CBD);\n* Suspicion of possible malignancy;\n* Pregnancy;\n* Diagnosis of liver cirrhosis (stage III or IV);\n* Insufficient language skills to be able to perform the quality-of-life questionnaires.",{"count":219,"type":21},276,[24],"This is a single-center, randomized controlled, parallel, non-inferiority trial. All adult patients with benign gallbladder disease with an indication for cholecystectomy will be assessed for eligibility and included after obtaining informed consent. A total of 276 patients will be randomized to undergo either robotic cholecystectomy (RC) or laparoscopic cholecystectomy (LC). The primary endpoint will be the incidence and severity of postoperative complications within 30 days after surgery. Secondary endpoints include perioperative outcomes, total health care utilization, health-related quality of life (HR-QoL) as assessed by patient-reported outcome measures, and cost-effectiveness. Follow-up assessments will be conducted at 7 and 30 days postoperatively.\n\nThis is the first randomized controlled trial designed to compare RC with LC in the treatment of benign gallbladder disease. The trial aims to evaluate the safety and non-inferiority of RC relative to LC, providing important evidence to guide the progress and adoption of robotic surgery in clinical practice.",[223,224,27,225,226],"Cholecystectomy, Robotic","Cholecystectomy, Laparoscopic","Gallstones","Benign Gallbladder Disease",[228,229,230,231,232],"Robotic cholecystectomy","Laparoscopic cholecystectomy","Benign gallbladder disease","Randomized controlled trial","Cost-effectiveness","2025-12-16",{"date":235,"type":45},"2025-12-23",{"date":237,"type":45},"2025-09-12",{"date":239,"type":21},"2026-06-01",{"name":241,"class":242},"Portsmouth Hospitals NHS Trust","OTHER_GOV",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":266},"100605119","research-on-identifying-critical-surgical-anatomy-in-cholecystectomy-videos-based-on-deep-learning-100605119","NCT07158372","Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning","Inclusion Criteria:\n\n* Patients aged 18 or above who are diagnosed by a doctor as needing laparoscopic cholecystectomy\n\nExclusion Criteria:\n\n* Patients who did not undergo surgery at the original hospital and those whose videos were blurry were excluded.",{"count":250,"type":21},200,"Laparoscopic cholecystectomy is a common surgical procedure, but it carries the potential for bile duct injury and other surgical risks. To provide visual assistance to surgeons during surgery and mitigate these risks, this research project aims to develop a real-time object recognition algorithm based on deep learning technology. This algorithm will label key anatomical structures in laparoscopic cholecystectomy videos, providing surgeons with immediate information on dangerous and safe areas.",[27,253],"Surgical Video Identification",[253,255,27,256],"Deep Learning","Artificial Intelligence","2025-08-28",{"date":259,"type":45},"2025-09-05",{"date":261,"type":45},"2025-08-15",{"date":263,"type":21},"2028-08-15",{"name":265,"class":242},"Chinese Academy of Sciences",5,{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":98},"100550474","comparison-between-low-pressure-pneumoperitoneum-with-high-pressure-pneumoperitoneum-in-post-operative-pain-shoulder-tip-pain-and-common-bile-duct-injuries-in-patients-undergoing-laparoscopic-cholecystectomy-100550474","NCT06447545","Comparison Between Low Pressure Pneumoperitoneum with High Pressure Pneumoperitoneum in Post-operative Pain, Shoulder Tip Pain and Common Bile Duct Injuries in Patients Undergoing Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Patients from both genders\n* Patients undergoing laparoscopic cholecystectomy for cholelithiasis.\n\nExclusion Criteria:\n\n* Patients with cardiac abnormalities.\n* Patients with previous abdominal surgeries.",{"count":274,"type":21},82,[24],"This study aims to address the existing gap in knowledge by conducting a comprehensive comparison of the incidence of pain and common bile duct injuries in patients undergoing laparoscopic cholecystectomy using Low pressure pneumoperitoneum versus high pressure pneumoperitoneum.",[27,278,279],"Pneumoperitoneum","Pain, Postoperative","2024-12-02",{"date":282,"type":45},"2024-12-04",{"date":284,"type":45},"2024-05-19",{"date":286,"type":21},"2025-11-30",{"name":288,"class":52},"Gulab Devi Hospital",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":98},"100552500","effect-of-ketalar-or-dexmedetomidine-on-increased-sensitivity-to-pain-following-treatment-with-remifentanil-100552500","NCT06473896","Effect of Ketalar or Dexmedetomidine on Increased Sensitivity to Pain Following Treatment With Remifentanil","Comparison of the Effect of Ketalar or Dexmedetomidine on Increased Sensitivity to Pain Induced Following Treatment With Remifentanil in Patients Undergoing a Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n• Patients who are about to undergo alaparoscopic cholecystectomy under general anesthesia\n\nExclusion Criteria:\n\n* Patients with sensitivity to the anesthetic\n* Patients with chronic pain who are in regular treatment\n* Urgent surgery\n* Patients with ischemic heart disease\n* Patients with known bradycardia\n* Patients with a pacemaker\n* Prolonged use of opiates\n* Kidney\u002Fliver function problems","85 Years",{"count":298,"type":21},90,[24],"Analgesia is one of the pillars of anesthesia. One of the common opiates for pain relief, with a short half-life, is Remifentanil. However, following Remifentanil treatment an increased sensitivity to pain \\[hyperalgesia\\] appears. The aim of the study is to compare the effects between complementary treatments, like Ketalar and Dexmedetomidine, in preventing increased sensitivity to pain after Remifentanil treatment",[27],"2024-08-05",{"date":304,"type":45},"2024-08-07",{"date":306,"type":45},"2024-04-18",{"date":308,"type":21},"2026-08-30",{"name":310,"class":242},"Assaf-Harofeh Medical Center",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":321,"studyType":168,"phases":4,"briefSummary":322,"conditions":323,"keywords":330,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":4},"100553047","algerian-cholecystectomy-outcomes-and-determinants-study-al-cods-100553047","NCT06481007","ALgerian Cholecystectomy Outcomes and Determinants Study (AL-CODS)","Algerian Cholecystectomy Outcomes and Determinants Study","AL-CODS","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Undergoing cholecystectomy.\n* Surgery performed in public or private hospitals in Algeria.\n* Surgery performed from January 1, 2025, to June 30, 2025.\n\nExclusion Criteria:\n\n* Patients younger than 18 years.\n* Patients refusing to participate.\n* Cholecystectomy performed for Gallbladder cancer.\n* Cholecystectomy performed outside the inclusion period.\n* Cholecystectomies performed in conjunction with other major surgeries.",{"count":320,"type":21},500,"1 Month","Cholecystectomy, the surgical removal of the gallbladder, is a common procedure performed to treat benign gallbladder diseases such as cholelithiasis (gallstones), cholecystitis (inflammation of the gallbladder), and biliary dyskinesia. While generally considered safe, this surgery can be associated with significant morbidity and mortality, particularly in certain populations or healthcare settings. Understanding these outcomes and the factors influencing them is crucial for improving patient care and surgical practices.\n\nIn Algeria, the healthcare landscape presents unique challenges and opportunities for evaluating surgical outcomes. Limited studies have specifically focused on the morbidity and mortality associated with cholecystectomy in this context. This study aims to fill that gap by providing comprehensive data on 30-day postoperative outcomes following cholecystectomy for benign gallbladder diseases in Algeria. Such data is essential for benchmarking current practices, identifying areas for improvement, and ultimately enhancing patient safety and surgical efficacy.",[27,324,325,326,327,328,329],"Adults","Gall Stone","Polyps","Pancreatitis Biliary","Gallbladder Dyskinesia","Cholecystitis",[331,27,332,333,334,335],"Algeria","mortality","morbidity","30 days","determinants","2024-06-26",{"date":338,"type":45},"2024-07-01",{"date":340,"type":21},"2025-01-01",{"date":342,"type":21},"2025-07-02",{"name":344,"class":52},"University of Oran 1"]